NCT07222722

Brief Summary

The primary objective of this study is to describe the pattern of renal tissue oxygen saturation (SrSO2) using near-infrared spectroscopy (NIRS) in premature infants \<30 weeks gestational age. The secondary objective of this study is to evaluate prenatal and postnatal risk factors for acute kidney injury (AKI) in premature infants \<30 weeks gestational age. The investigators will also compare various rates of complications including death, length-of-stay, and prolonged duration of mechanical ventilation, among others.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 29, 2025

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 30, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

November 1, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

October 30, 2025

Status Verified

October 1, 2025

Enrollment Period

5 months

First QC Date

October 29, 2025

Last Update Submit

October 29, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Average NIRS Value (SrSO2)

    NIRS values measured as renal tissue oxygen saturation (SrSO2); measured continuously over first 7 days of life.

    Up to Day-of-life 7

Secondary Outcomes (5)

  • Serum Creatinine Values

    Day-of-life 1, Day-of-life 3, Day-of-life 7, Day-of-life 14

  • Average Urine Output

    Up to Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)

  • Length-of-Stay in NICU

    Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)

  • Duration of Non-Invasive Ventilation

    Up to Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)

  • Duration of Mechanical Ventilation

    Up to Day of NICU Discharge (Approximately Day-of-life 7; subject to large individual variations)

Study Arms (1)

NICU patients born less than 30 weeks gestational age

EXPERIMENTAL

All patients included in the study will be assigned to receive NIRS monitoring.

Device: NIRS Monitoring

Interventions

The renal NIRS device is a non-invasive tool that uses near-infrared light to measure oxygen saturation various tissues. Renal NIRS sensors will be placed by 24 hours of the participants' admission.

NICU patients born less than 30 weeks gestational age

Eligibility Criteria

Age24 Weeks - 30 Weeks
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Any neonate less than 30 weeks in gestational age
  • Willingness and capacity of both adult parents/guardians to sign consent

You may not qualify if:

  • An infant with known congenital anomalies of the kidney (i.e., grade 4 or 5 vesicoureteral reflux (VUR), posterior urethral valves, moderate or severe hydronephrosis, autosomal recessive polycystic kidney disease (ARPKD), bilateral renal agenesis or dysplasia)
  • Age \>30 weeks gestational age
  • Age \<24 weeks and \<500 grams (will be excluded due to sensitivity of skin in this vulnerable population).
  • Clinician's decision that NIRS is not suitable due to the patient's clinical condition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NYU Langone Health

New York, New York, 10016, United States

RECRUITING

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Sourabh Verma, MD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 29, 2025

First Posted

October 30, 2025

Study Start

November 1, 2025

Primary Completion

April 1, 2026

Study Completion

April 1, 2026

Last Updated

October 30, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will share

The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Jordan.nelson@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access Criteria
The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Jordan.nelson@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

Locations